{"filings":[{"id":2273438,"accession_number":"0001213900-26-090241","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2026-08-14T21:01:28+00:00","items":["1.01","9.01"],"status":"ready","headline":"HeartBeam enters ATM equity offering agreement for up to $25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Titan Partners Securities LLC allows sale of up to $25M of common stock.","Sales via at-the-market offerings on Nasdaq under shelf registration S-3 (Reg. No. 333-293307).","Commission of up to 3% of gross sales price per share to sales agent.","Prospectus supplement filed August 14, 2026; shares sold from time to time at market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2087608,"accession_number":"0001213900-26-085822","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K/A","filed_at":"2026-08-05T22:16:58+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam finalizes separation with former officer Robert P. Eno; $300K cash, equity acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert P. Eno's employment terminated June 30, 2026; separation agreement executed July 30, 2026.","Lump sum cash payment of $300,000 (9 months base salary) plus up to 9 months COBRA reimbursement.","Full acceleration of vesting on all outstanding stock options and RSUs; option exercise period extended to Dec 31, 2027.","Eno will serve as non-employee advisor under Advisory Agreement with $1,000 retainer fee.","Separate fully vested RSU award of 232,400 shares granted in lieu of 2025 bonus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2024605,"accession_number":"0001213900-26-084622","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2026-08-03T20:15:27+00:00","items":["5.07"],"status":"ready","headline":"HeartBeam shareholders reject proposal to increase authorized shares by 3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Seven director nominees elected; Richard Ferrari received 10.4M votes for, 1.3M against.","Ratification of CBIZ CPAs P.C. as independent auditor approved with 28.6M votes for.","Proposal to amend 2022 Equity Incentive Plan to add 3M shares failed: 3.96M for, 7.82M against.","Quorum of 52.34% of outstanding shares represented at the July 31, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1415357,"accession_number":"0001213900-26-074979","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2026-07-02T20:15:31+00:00","items":["3.01"],"status":"ready","headline":"HeartBeam receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 30, 2026 for non-compliance with minimum bid price of $1.00 per share.","Has 180 calendar days, until December 28, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by Dec 28, may qualify for a second 180-day period if other listing standards are met.","Company will evaluate options but cannot assure compliance; failure could lead to delisting and appeal rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1252076,"accession_number":"0001213900-26-071605","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2026-06-24T21:28:27+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"HeartBeam announces strategic shift to license 3D ECG tech; CEO Eno departs, Vajdic takes PEO role","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Robert Eno and board mutually agreed to his departure effective June 30, 2026; he will remain as a consultant.","Board member Mark Strome resigned immediately; no dispute with company cited.","Company will license its 3D ECG signal technology to partners, moving away from direct device sales.","Operations realigned under President Branislav Vajdic (PEO) and Executive Chairman Rich Ferrari.","New strategy targets heart attack detection, AI-ready signal, and global partnerships; cost structure expected to decrease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1195205,"accession_number":"0001213900-26-070628","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2026-06-22T20:15:22+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam grants 2.8M PRSUs to President Vajdic; approves transaction bonus on change in control","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["2,800,000 performance-based RSUs granted to President/Founder Branislav Vajdic under 2022 Equity Incentive Plan.","RSUs vest over 3 years subject to operational/clinical milestones and continued service.","Transaction bonus provides up to 2% of Aggregate Price Paid if market cap thresholds met in a change in control.","Bonus payable in same form as stockholder consideration; no bonus if minimum market cap not achieved.","Accelerated vesting on qualifying termination before 3-year anniversary if milestones timely achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95369,"accession_number":"0001213900-26-044672","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"HeartBeam closes $10M public offering of 12.5M shares at $0.80 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 12.5M shares at $0.80, gross proceeds $10M; underwriter option for 1.875M additional shares.","Offering led by ClearCardio (first commercial customer), management, board, and existing investors.","Net proceeds to fund commercialization of FDA-cleared synthesized ECG system, extended-wear patch, heart attack detection, AI, and working capital.","Titan Partners Group acted as sole bookrunner; offering closed April 16, 2026.","Common stock (BEAT) and warrants (BEATW) trade on NASDAQ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124842,"accession_number":"0001213900-25-113353","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"HeartBeam receives FDA NSE letter for 12-Lead ECG Synthesis 510(k), will seek resolution","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued a Not Substantially Equivalent (NSE) letter for HeartBeam's 12-Lead ECG Synthesis Software 510(k) on Nov 20, 2025.","Company stands behind its clinical data and will work with FDA to resolve the NSE determination.","HeartBeam is evaluating launching its 3D ECG system, which received FDA clearance in December 2024.","No financial impact or guidance change disclosed; product approval timeline uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141546,"accession_number":"0001213900-25-064580","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"HeartBeam shareholders approve 3M share increase to equity plan, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted to increase authorized shares under 2022 Equity Plan by 3M from 8.9M to 11.9M.","All nine director nominees elected with majority votes; broker non-votes of 11.6M on each nominee.","Ratification of CBIZ CPAs as auditor approved with 18.4M for, 55.9k against, 257.5k abstentions.","Equity plan amendment passed with 4.38M for, 2.72M against, 11.58M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159393,"accession_number":"0001213900-25-039490","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"HeartBeam CEO Robert Eno appointed to Board of Directors effective May 5, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Robert Eno joins Board effective May 5, 2025; Board expands from 8 to 9 members.","Eno has 30+ years medtech experience, previously CEO of Preview Medical, leadership at HeartFlow, OptiMedica.","Appointment supports commercialization of HeartBeam's 3D ECG technology; FDA clearance for 3D ECG received Dec 2024.","12-lead ECG Synthesis Software FDA application submitted Jan 2025; Early Access Program underway for clinical feedback.","Executive Chairman cites Eno's go-to-market expertise as key to strategic oversight and growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159392,"accession_number":"0001213900-25-035509","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"HeartBeam auditor resigns; CBIZ CPAs engaged; going concern noted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor on April 21, 2025, due to CBIZ CPAs acquiring its attest business.","Audit committee engaged CBIZ CPAs as new independent auditor for fiscal year ending Dec 31, 2025.","2024 audit report included a going-concern explanatory paragraph; no adverse opinions on prior periods.","Material weaknesses in internal controls were reported and disclosed as remediated in 2024 10-K.","No disagreements or reportable events occurred during the past two fiscal years or interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177788,"accession_number":"0001213900-25-017245","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HeartBeam raises additional ~$1.5M from over-allotment exercise in public offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriter exercised over-allotment for 864,033 shares at $1.70, gross proceeds ~$1.5M.","Total offering increased to 6,746,386 shares and ~$11.5M gross proceeds.","Proceeds for commercial-readiness activities, R&D, regulatory projects, and working capital.","MDB Capital acted as underwriter; Paulson Investment participated as selected dealer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177787,"accession_number":"0001213900-25-014528","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"HeartBeam prices $10M public offering of 5.88M shares at $1.70 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,882,353 shares of common stock at $1.70/share; gross proceeds ~$10M.","Underwriter granted 588,235 warrants at $2.125/share, exercisable from Feb 2026 to Feb 2030.","Directors and officers subject to 180-day lock-up; company restricted from issuing equity for 180 days.","Net proceeds to fund commercial-readiness, R&D, regulatory projects, working capital.","FDA cleared HeartBeam system for arrhythmia; 510(k) submitted for 12-lead ECG synthesis software."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194493,"accession_number":"0001628280-24-043338","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"HeartBeam appoints Robert Eno as CEO; founder Vajdic moves to President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Eno named CEO effective Oct 21, 2024; base salary of $400,000 with 60% incentive bonus.","Founder Branislav Vajdic transitions to President, focusing on vector-based technology and AI.","Eno brings 30+ years of MedTech go-to-market experience; previously SVP Marketing at HeartFlow.","Company continues to pursue FDA 510(k) clearance for its credit card-sized ECG device.","No changes to Vajdic's compensation; transition described as long-planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210823,"accession_number":"0001628280-24-039968","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam appoints Timothy Cruickshank as CFO; base salary $385K plus equity","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Cruickshank appointed CFO effective September 9, 2024.","Annual base salary of $385,000; eligible for 45% incentive bonus and 400,000-share option grant.","Cruickshank was CFO of ImpediMed from Oct 2019 to Mar 2024 with 15+ years medtech experience.","Succeeds Richard Brounstein, who retired in February and remained in advisory capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229229,"accession_number":"0001213900-24-053485","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"HeartBeam shareholders approve 3M share increase to equity plan and elect eight directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to 2022 Equity Plan, increasing authorized shares from 5.9M to 8.9M (3M increase).","Eight directors elected (Ferrari, Vajdic, de Urioste, Ortigas-Wedekind, Elfrink, Strome, Nelson, Jaff).","Ratified Marcum LLP as independent auditor for fiscal year ending December 31, 2024.","Quorum of 15,510,613 votes (58.91% of outstanding shares) at June 12, 2024 annual meeting.","Broker non-votes of ~6.9M were recorded on director election and equity plan amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229228,"accession_number":"0001779372-24-000005","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"HeartBeam enters $17M at-the-market equity facility with Public Ventures, terminates prior AGP deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New ATM sales agreement with Public Ventures allows sale of up to $17M of common stock at 3% commission.","Prior ATM agreement with A.G.P./Alliance Global Partners was terminated on May 1, 2024.","Net proceeds will be used for working capital and general corporate purposes.","Sales will occur from time to time at the Company's discretion; no assurance of any sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247817,"accession_number":"0001779372-24-000001","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam CFO Richard Brounstein retires effective Feb 1, 2024; no successor named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Brounstein retired as CFO effective February 1, 2024; he served since 2015.","Brounstein will provide CFO advisory consulting services to assist transition.","No replacement CFO has been announced; CEO Branislav Vajdic signed the filing.","Retirement not due to disagreement with company or board (as stated)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282453,"accession_number":"0001779372-23-000019","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam appoints Dr. Michael R. Jaff to board effective July 24, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to 8 directors to accommodate appointment of Dr. Jaff.","Dr. Jaff is CMO and VP at Boston Scientific; former Harvard professor and hospital president.","He is founder of VasCore and Past-President of the Society for Vascular Medicine.","No family relationships or related party transactions reported with the new director.","Press release announcing appointment issued on July 26, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282452,"accession_number":"0001213900-23-056219","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"HeartBeam shareholders approve increase in equity plan shares to 5.9M from 1.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected all five director nominees: Ferrari, Vajdic, de Urioste, Ortigas-Wedekind, Elfrink.","Ratified Marcum LLP as independent auditor for FY2023 with 17,691,638 votes for, 8,471 against.","Amendment to 2022 Equity Incentive Plan approved; authorized shares increased by 4M to 5.9M.","Votes for the plan amendment: 13,469,751 for, 788,072 against, 3,460,395 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301676,"accession_number":"0001779372-23-000015","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam adds two directors; CFO Brounstein to retire Oct 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Strome and Ken Nelson appointed to board effective June 5, 2023, expanding board from 5 to 7.","Strome (investment veteran) will serve on Compensation Committee.","Nelson brings 20 years of digital health and cardiac remote monitoring experience.","CFO Richard Brounstein announced retirement effective Oct 31, 2023; will provide advisory services for transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301675,"accession_number":"0001779372-23-000013","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HeartBeam regains Nasdaq compliance with $23.2M equity offering of 16.67M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency notice for stockholders' equity below $2.5M on Mar 20, 2023.","Submitted compliance plan to Nasdaq on May 3, 2023.","Completed secondary offering of 16,666,666 shares at $1.50/share, net proceeds $23.2M.","Company believes it regained compliance with Nasdaq Listing Rule 5550(b)(1).","Nasdaq will monitor ongoing compliance; failure at next periodic report could lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301674,"accession_number":"0001213900-23-036932","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"HeartBeam raises ~$1.4M in registered direct offering of 1M shares at $1.50/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,000,000 shares of common stock at $1.50/share to an accredited investor.","Net proceeds after fees and expenses approximately $1.4 million.","Engaged A.G.P./Alliance Global Partners as financial advisor for $70,000 fixed fee.","Offering conducted via shelf registration statement on Form S-3 (File No. 333-269520)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301673,"accession_number":"0001779372-23-000009","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"HeartBeam closes $25M secondary offering; shifts commercial launch to 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 16.67M shares at $1.50/share closed on May 2, 2023; net proceeds $23.2M.","No material commercial revenue expected in 2023; cash runway extended into late 2024.","Company to focus on FDA 510(k) clearance for HeartBeam AIMIGo 12-lead equivalence; submission planned late 2023.","Strategic shift to delay commercial launch until after 12-lead equivalence clearance, targeting 2024.","Placement agent Public Ventures received warrants for 1.67M shares; $10M of proceeds earmarked for FDA work and limited market releases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321445,"accession_number":"0001779372-23-000007","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"HeartBeam receives Nasdaq deficiency notice for failing minimum $2.5M equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Reported stockholders' equity of $2.374M as of Dec 31, 2022, below the $2.5M minimum.","Company has 45 days (until May 4, 2023) to submit a compliance plan to Nasdaq.","If plan accepted, HeartBeam has until Sept 18, 2023 to regain compliance.","Stock and warrants continue trading; delisting would materially affect capital access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321444,"accession_number":"0001213900-23-019312","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"HeartBeam launches $15M public offering; reports positive trial results for portable 12-lead ECG","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["$15M public offering of common stock; proceeds for clinical/reg ($2M), R&D ($7M), sales/mkt ($1M), G&A ($5M).","HIDES study: VECG sensitivity 93%, specificity 95% vs cardiologist 70%/83% for early MI detection.","First 510(k) submission for recording device in Q1 2023; second for synthesized 12-lead in Q4 2023; clearances expected in 12 months.","Credit-card-sized device can replicate 12-lead ECG; holds foundational patents in portable VECG.","Management includes CEO Branislav Vajdic, CFO Rick Brounstein; advisor panel includes key cardiologists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321443,"accession_number":"0001213900-23-018655","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"HeartBeam amends financing agreements, reducing available equity and note amounts to $4M each","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended Securities Purchase Agreement with Maverick Capital reduces total common stock available from $5M to $4M.","Amended Note Purchase Agreement reduces principal of convertible notes available from $5M to $4M at 6% interest.","Issued 200,105 shares for $500,000 gross proceeds under the SPA on March 7, 2023.","Issued $500,000 convertible note on March 1, 2023, which was fully repaid with interest on March 7, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321442,"accession_number":"0001779372-23-000005","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam CBO Jon Hunt steps down; President Robert Eno assumes duties","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Hunt resigns as CBO effective March 15, 2023; remains as strategic advisor/consultant.","President Robert Eno assumes CBO duties; no disagreement cited for the transition.","Company cites Hunt's desire for work-life balance after nearly four decades in the industry.","Key 2023 milestones include FDA clearance for AIMI system and FDA submission for AIMIGo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321441,"accession_number":"0001779372-23-000004","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"HeartBeam enters up to $10M equity and convertible note facility with Maverick Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $5M common stock at 75% of VWAP; initial $500K drawdown on 6% convertible note issued March 1, 2023.","Convertible notes bear 6% interest, convertible at 75% of VWAP; shares registered on Form S-3.","Proceeds used for general corporate purposes and working capital; equity blocker limits beneficial ownership to 4.99%.","Drawdowns up to $500K each, with 5-trading-day pricing periods; facility expires May 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321440,"accession_number":"0001213900-23-006955","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"HeartBeam enters into $13M at-the-market equity sales agreement with A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $13M of common stock may be sold through A.G.P. in at-the-market offerings under existing S-3.","A.G.P. receives a 3.0% commission on gross proceeds from each sale of shares.","Net proceeds intended for working capital and general corporate purposes.","Sales agreement dated February 1, 2023; company may issue shares from time to time at its option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321439,"accession_number":"0001779372-23-000001","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam appoints Robert Eno as President effective Jan 18, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Eno appointed as President effective Jan 18, 2023, a newly created role.","Annual salary of $360,000; eligible for incentive bonus up to 40% of base salary.","Granted option to purchase 240,000 shares of common stock under 2022 Stock Plan.","Eno brings 28+ years medical tech experience; previously CEO of PreView Medical, SVP Marketing at HeartFlow.","No family relationships or related party transactions with current officers/directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339568,"accession_number":"0001779372-22-000048","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2022-11-17T23:59:59+00:00","items":["5.03","5.07"],"status":"ready","headline":"HeartBeam shareholders approve increase in authorized common stock to 100M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Nov 14, 2022; 75.95% of outstanding shares represented.","Authorized common stock increased to 100M shares; 5.6M for, 457K against.","Authorized 10M shares of blank check preferred stock; 4.6M for, 223K against.","Amendment filed with Delaware Secretary of State effective Nov 16, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356924,"accession_number":"0001779372-22-000039","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2022-09-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"HeartBeam dismisses Friedman LLP and engages Marcum LLP as independent auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Effective Sept 1, 2022, Friedman merged with Marcum; on Sept 19, Audit Committee dismissed Friedman and engaged Marcum.","No disagreements or reportable events with Friedman during fiscal 2020, 2021, or subsequent interim period through Sept 19.","Friedman's reports on HeartBeam's 2020-2021 financials contained no adverse opinion or qualification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356923,"accession_number":"0001779372-22-000035","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"HeartBeam COO Alan Baumel resigns, transitions to Operations Analyst role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan Baumel resigned as COO effective Aug 15, 2022, moving to non-officer Operations Analyst role.","Transition was pre-planned; Baumel had expressed desire for part-time teaching in 2023.","No disagreement with Company or board; not related to operations, policies, or practices.","No replacement for COO position announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356922,"accession_number":"0001779372-22-000033","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"HeartBeam appoints Ken Persen as CTO; enters LIVMOR partnership amendment","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ken Persen named CTO effective Aug 2, 2022; $300k annual salary, bonus up to 30% tied to FDA submission and corporate goals, 80k stock option.","Entered supplemental agreement with LIVMOR: paid $200k for source code access; licenses become non-exclusive, perpetual, royalty-free.","Persen previously LIVMOR CTO/CEO; over 28 years in cardiac devices and digital health, including Guidant and Cameron Health.","Partnership to create a company-branded version of LIVMOR's Halo+ remote patient monitoring solution for physicians and patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375416,"accession_number":"0001779372-22-000019","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"HeartBeam stockholders elect directors, ratify auditor, approve 2022 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five nominees elected: Richard Ferrari, Branislav Vajdic, George de Urioste, Marga Ortigas-Wedekind, Willem Elfrink with 4.28M-4.38M votes for each.","Ratification of Friedman, LLP as auditor for FY2022 approved with 4,920,198 votes for, 12,742 against.","2022 Equity Incentive Plan approved with 4,125,267 for, 147,122 against; plan authorizes up to 1.9M new shares plus shares from prior plan.","Quorum of 62.55% of outstanding shares represented; 572,675 broker non-votes on director and plan proposals.","Plan includes automatic annual share reserve increase of the lesser of 3.8M shares or 5% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393779,"accession_number":"0001779372-22-000010","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"HeartBeam partners with Triple Ring to co-develop 3D vector ECG device; FDA submission targeted by Q4 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five-phase expedited project includes device builds for verification, validation, packaging and manufacturing transfer.","Credit card-sized 3D vector ECG recorder via smartphone app; cloud-based diagnostic suggestion and 12-lead synthesis.","Targeting FDA 510(k) submission in Q4 2022; discussions with contract manufacturers underway.","Triple Ring brings medtech co-development expertise from early R&D through regulatory approval and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393778,"accession_number":"0001779372-22-000007","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["1.01","3.01","3.02","9.01"],"status":"ready","headline":"HeartBeam raises $348k in private placement with OpenSky Opportunities Fund Ltd.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into stock purchase agreement to sell 58,000 units at $6/unit; each unit consists of one share and one warrant.","Warrants exercisable at $6.00 per share, subject to 180-day lockup, expiring five years from issuance.","Net proceeds of $348,000; no underwriting discounts; proceeds for general working capital and corporate purposes.","Securities issued in unregistered private placement under Section 4(a)(2) and Rule 506; purchaser represents accredited investor status."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393777,"accession_number":"0001779372-22-000005","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"HeartBeam partners with LIVMOR for RPM platform; terminates Ximedica deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnered with LIVMOR to build HeartBeam-branded version of LIVMOR's FDA-cleared Halo+ RPM portal for physicians and patients.","Terminated prior development agreement with Ximedica, effective January 31, 2022, to proceed with LIVMOR partnership.","Customized HeartBeam Platform intended to support FDA submission of heart attack detection software for ED settings later in 2022.","Development fees paid in two equal installments; term of three years with automatic renewal unless terminated.","Senior executives of both companies will supervise the project; LIVMOR provides regulatory support for FDA clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412315,"accession_number":"0001779372-21-000003","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2021-12-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam appoints Alan Baumel as COO effective Dec 20, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual salary of $200,000, bonus eligibility post-IPO, and option for 1% of post-IPO shares.","Bring 35+ years MedTech experience; previously SVP at Bardy Diagnostics (Hillrom) and roles at Gore, Medtronic, Boston Scientific-acquired firms.","Will lead product development, manufacturing, quality, and regulatory affairs to accelerate commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412314,"accession_number":"0001213900-21-060287","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2021-11-17T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"HeartBeam completes $16.5M IPO; net proceeds $14.9M for ECG product development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 2.75M units at $6/unit; each unit includes one share and one warrant exercisable at $6 for 5 years.","Gross proceeds $16.5M, net proceeds $14.9M after underwriting discounts and offering expenses.","Common stock and warrants trade on Nasdaq under symbols BEAT and BEATW.","Proceeds to fund FDA 510(k) clearance and commercial launch of ER and telehealth products.","Granted 87k options to CBO John Hunt and 44k options to director George de Urioste at $4.25 strike, vesting over 48 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}